Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HL06/WBP299 in unresectable or metastatic melanoma
CTR20190661Phase 2Active
- Sponsor
- Hualan Ankang Biotechnology
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HL06/WBP299 in melanoma, sponsored by Hualan Ankang Biotechnology. Started Apr 2020; status: active.
02
Drugs
HL06/WBP299
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20190661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190661.